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HPV vaccine: Can we afford to 
hesitate?
To the Editor: Cervical cancer, caused by human papillomavirus 
(HPV) infection, is highly prevalent in sub-Saharan Africa. The 
estimated annual incidence of cervical cancer is 35/100 000 women, 
with 22.5/100  000 associated deaths. This is in stark contrast to the 
6.6/100  000 cases and 2.7/100 000 deaths reported in developed 
countries such as the USA, where HPV vaccination has been available 
since 2006.[1.2]
A vaccine is only approved after extensive clinical trials prove that 
the benefits of vaccination outweigh any possible risks associated with 
it. Governmental and non-governmental health organisations scrutinise 
these clinical trial data through independent medicines review agencies 
and academic institutions before vaccines are approved and accepted 
for use (Table 1). Currently, two commercially available HPV vaccines 
are approved in more than 130 countries, and more than 175 million 
doses have been distributed world wide.[3] The USA and Austria in 2006, 
Australia, Canada, Belgium, France, Germany and Italy in 2007, and 
the UK and others in 2008 were among the first countries to introduce 
HPV vaccination as part of their national immunisation programmes.[2] 
To date, HPV vaccination has been introduced into national vaccination 
programmes in at least 40 countries,[4] almost all of which have have 
lower cervical cancer prevalences than South Africa (SA).[2]
The safety of both HPV vaccines has been rigorously tested 
in clinical trials prior to licensing and as part of ongoing post-
marketing surveillance.[2] Data from post-licensure passive, active 
and population-based epidemiological surveillance studies have not 
shown any differences in conditions such as Guillain-Barré syndrome, 
stroke, appendicitis, seizures, allergic reactions, anaphylaxis and 
venous thromboembolism.[2,5] Reputable global leading health 
organisations, including the South African HPV Advisory Board, 
endorse the safety and efficacy of HPV vaccination (Table 1).[6]
Both vaccines showed almost 100% efficacy against precancerous 
lesions associated with HPV types 16 and 18, which are responsible 
for around 70% of cervical cancers. Cross-protection was also 
reported against some non-vaccine types, which could increase 
protection to up to 85% of cervical cancers.[7] Cancer endpoints will 
take decades to observe, and it would not be ethical to allow women 
in a placebo arm of a trial to develop cervical cancer. Several proximal 
measures of vaccine efficacy such as persistent infection with HPV, 
incidence of cervical precancers and genital warts, and markers of 
immunogenicity were therefore used in previous studies. These are 
now accepted by the World Health Organization for use in future 
vaccine trials as appropriate endpoints that accurately predict vaccine 
efficacy against cancer.[4] Data from ongoing follow-up studies show 
that HPV vaccines are effective for at least 9.4 years; levels plateau 
early and then stay unchanged, so mathematical modelling studies 
have predicted long-lasting protection for at least 20 years. In 
addition, antibody levels, and therefore predicted vaccine efficacy, 
are highest in girls who receive the HPV vaccine at a younger age, 
providing a strong incentive for early vaccination.[4]
It can be expected that antivaccine campaigners will take advantage 
of the HPV vaccine debate, focusing on concerns about safety and 
isolated reports of adverse events temporally related to vaccination. 
It is imperative that healthcare professionals are well informed so 
they are able to answer questions and dispel the myths surrounding 
HPV vaccination in order to ensure maximum vaccine coverage 
and herd immunity. The National Department of Health and the SA 
government are applauded for the bold decision to implement and 
finance this lifesaving initiative. It deserves the full support of all 
medical professionals!
Submitted on behalf of the following members of the South African 
HPV Advisory Board: M H Botha, N Cooreman, G Dreyer, N P Godi, 
F Guidozzi, B Koller, B G Lindeque, C Maske, J Moodley, M Moodley, 
A Mouton, K L Richter, L Rogers, T Slavik, T Smith, R Soeters, C Turner, 
K Voyi, J Whittaker and A Williamson.
The SA HPV Advisory Board is an independent group of clinicians 
and experts with a special interest in HPV-related disease. The Board is 
affiliated to the SA Society of Gynaecologic Oncology and the SA Society 
of Obstetricians and Gynaecologists. 
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Table 1. Summary of selected leading health organisations that endorse the safety and efficacy of HPV vaccination
Organisation/journal Available from
World Health Organization’s Global Advisory Committee on 
Vaccine Safety 
http://www.who.int/wer/2013/wer8829.pdf
http://www.who.int/vaccine_safety/committee/topics/hpv/130619HPV_
VaccineGACVSstatement.pdf
http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_
Evidence_based_recommendationsWHO_with_Appendices2_3.pdf 
International Federation of Gynecology and Obstetrics http://www.figo.org/files/figo-corp/Statement%20on%20Safety%20of%20
HPV%20vaccination%20-%20FINAL%20-%20AUGUST%202013.pdf 
Global Alliance for Vaccines and Immunisation. Partners 
include UNICEF, United Nations, Bill & Melinda Gates 
Foundation, World Bank
http://www.gavialliance.org/support/nvs/human-papillomavirus-vaccine-
support/ 
National Cancer Institute, National Institutes of Health, USA http://www.cancer.gov/cancertopics/factsheet/prevention/HPV-vaccine 
Advisory Committee on Immunization Practices, Centers for 
Disease Control and Prevention, USA
http://www.cdc.gov/hpv/vaccine.html 
http://www.cdc.gov/hpv/vaccinesafety.html http://www.cdc.gov/vaccines/hcp/
acip-recs/vacc-specific/hpv.html 
American College of Obstetricians and Gynecologists http://www.acog.org/Resources%20And%20Publications/Committee%20
Opinions/Committee%20on%20Adolescent%20Health%20Care/Human%20
Papillomavirus%20Vaccination.aspx
European Medicines Agency, European Union http://ec.europa.eu/health/sti_prevention/hpv/index_en.htm 
Medicines and Healthcare Products Regulatory Agency, UK http://www.mhra.gov.uk/Safetyinformation/
Generalsafetyinformationandadvice/Product-
specificinformationandadvice/Product-specificinformationandadvice-G-L/
HumanpapillomavirusHPVvaccine/index.htm 
Joint Committee on Vaccination and Immunisation, UK http://clinicalvirology.org/~ukcvn/images/stories/aboutus%20linkspdf/HPV_
JCVI_report_18_07_2008virvacc.pdf 
Karolinska Institutet, Sweden http://ki.se/ki/jsp/polopoly.jsp?d=2637&a=168933&l=en&newsdep=2637 
Paul Elrich Institut, Agency of the German Federal Ministry 
of Health
http://www.pei.de/SharedDocs/Downloads/vigilanz/bulletin-zur-arzneimittelsi
cherheit/2013/3-2013.pdf?__blob=publicationFile&v=4 
Immunise Australia Program, Australian Government 
Department of Health and Ageing
www.australia.gov.au/hpv 
National Centre for Immunisation, Research and 
Surveillance, Australia
http://www.ncirs.edu.au/immunisation/fact-sheets/hpv-human-
papillomavirus-fact-sheet.pdf 
Ministry of Health, Malaysia http://www.moh.gov.my/attachments/8106 
South African HPV Advisory Board (affiliated to the South 
African societies of Obstetricians and Gynaecologists and 
Gynaecological Oncologists)
http://www.sasog.co.za/B_HPVPROPHYLACTICVACCINE.asp 
http://www.sajgo.co.za/index.php/sajgo/article/view/60/pdf_23
Cancer Association of South Africa http://www.cansa.org.za/files/2013/11/Fact-Sheet-Human-Papilloma-Virus-
Infection-Cancer-Nov-2013.pdf 
HPV = human papillomavirus.
